Correlation of Oncotype DX Recurrence Score with Cyclin D1 and ErbB2.
Misra D, Adelson K, Halpern M, Jaffer S, Nagi C, Bleiweiss I, Mandeli J, Raptis G, Germain D. Correlation of Oncotype DX Recurrence Score with Cyclin D1 and ErbB2. Cancer Research 2009, 69: 3035-3035. DOI: 10.1158/0008-5472.sabcs-09-3035.Peer-Reviewed Original ResearchNode-negative breast cancerOncotype DX recurrence scoreOncotype DXRecurrence scoreDX recurrence scoreNegative breast cancerBreast cancerTamoxifen resistanceCyclin D1 overexpressionCyclin D1Cyclin D1 expressionFree survivalOverall survivalEarly-stage node-negative breast cancerColorectal Cancer Study GroupLower relapse-free survivalTamoxifen-resistant breast cancerD1 expressionAdjuvant tamoxifen therapyCancer Study GroupProgression-free survivalUse of chemotherapyResistant breast cancerHigh cyclin D1 expressionHigh recurrence scoreBortezomib Enhances the Efficacy of Fulvestrant by Promoting the Aggregation of the Estrogen Receptor in the Cytoplasm.
Germain D, Bahadur U, Halpern M, Adelson K, Raptis G, Waxman S, Ishii Y. Bortezomib Enhances the Efficacy of Fulvestrant by Promoting the Aggregation of the Estrogen Receptor in the Cytoplasm. Cancer Research 2009, 69: 5142-5142. DOI: 10.1158/0008-5472.sabcs-09-5142.Peer-Reviewed Original ResearchEfficacy of fulvestrantEstrogen receptorAromatase inhibitorsBreast cancer mouse modelPost-menopausal womenCancer mouse modelProteasome inhibitor bortezomibUnfolded protein responseEndometrial cancerPremenopausal womenFulvestrant resistanceStandard treatmentTamoxifen resistanceFulvestrant treatmentTumor regressionAgonist effectsClinical trialsBreast cancerMouse modelFulvestrantTherapeutic benefitConverts androgensAdipose tissueInhibitor bortezomibBortezomib